Prostate risk (IPSS), erectile function (IIEF-5), stone risk, hematuria evaluation, and urinary tract indices.
Bosniak classification of renal cystic masses (v2019 update).
Cancer of the Prostate Risk Assessment post-surgical score.
Clinical prediction of ureteral stones in renal colic (0-13).
EAU non-muscle-invasive bladder cancer risk stratification.
EAU localized prostate cancer risk stratification.
EORTC risk tables for non-muscle-invasive bladder cancer (Sylvester 2006).
Estimate bladder capacity (pediatric Koff formula; adult typical).
Provides prognostic grading system for clear cell renal cell carcinoma (RCC) based on nuclear morphology and cellular appearance. Independent predictor of cancer-specific survival that correlates nuclear grade with prognosis.
Histologic grading system for prostate cancer based on microscopic tumor architecture patterns. Uses primary and secondary tumor patterns to predict prognosis and guide treatment decisions. The score combines the two most prevalent architectural patterns found in the tumor specimen.
Grades percutaneous nephrolithotomy complexity from stone burden and renal anatomy; predicts stone-free rate.
Brief 3-scored-item questionnaire quantifying urinary incontinence severity and impact.
5-item abridged International Index of Erectile Function grading ED severity.
Measures severity of benign prostatic hyperplasia (BPH) symptoms using 7 questions about urinary symptoms to guide treatment decisions.
EAU 2021 risk stratification for non-muscle-invasive bladder cancer (NMIBC): low, intermediate, high, or very high risk of recurrence/progression from tumor number, size, prior recurrence rate, T category, concomitant CIS, and grade.
Overactive Bladder Symptom Score (Homma 2006): daytime frequency (0-2), nighttime frequency (0-3), urgency (0-5), urgency incontinence (0-5); total 0-15. ≤5 mild, 6-11 moderate, ≥12 severe.
5-item screening for premature ejaculation: <=8 no PE, 9-10 probable PE, >=11 PE.
Percent free PSA = (free PSA / total PSA) × 100. In the total PSA 4-10 ng/mL range: >25% low, 10-25% intermediate, <10% high probability of prostate cancer on biopsy.
The Beckman Coulter Prostate Health Index combines total PSA, free PSA and [-2]proPSA: phi = (p2PSA / fPSA) x sqrt(tPSA). Validated for men >=50 with PSA 4-10 ng/mL and non-suspicious DRE.
PSA divided by prostate volume; >= 0.15 ng/mL/cc raises suspicion for prostate cancer.
Quantifies anatomic complexity of renal masses (4-12): low 4-6, moderate 7-9, high 10-12.
Testicular Workup for Ischemia and Suspected Torsion (TWIST) score (Barbosa): 5-item clinical score predicting testicular torsion in acute scrotum. Swelling (2), hard testicle (2), absent cremasteric reflex (1), nausea/vomiting (1), high-riding testicle (1). Total 0-7 stratifies risk and urgency of management.
Clinical Decision Support (CDS) Notice & Legal Disclaimer
All calculations and clinical scoring tools in this directory are intended strictly for educational and decision-support use by licensed medical practitioners. They do not constitute autonomous medical advice or direct treatment orders. See the full DexaMed Medical Disclaimer.